Skip to content

The Proportion of Patients Diagnosed With Dry Eye by the Asia Dry Eye Society (ADES) Criteria in Taiwan (DECS-TW)

Dry Eye Cross-Sectional Study-Taiwan (DECS-TW): Observational, Multicenter, Cross-Sectional Study on Dry Eye Disease in Taiwan

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT05096546
Acronym
DECS-TW
Enrollment
540
Registered
2021-10-27
Start date
2021-10-21
Completion date
2022-07-31
Last updated
2022-05-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Dry Eye Syndromes

Keywords

Dry eye disease, Asia Dry Eye Society (ADES) criteria, Taiwanese population

Brief summary

The study aims to determine the proportion of patients diagnosed with dry eye by the Asia Dry Eye Society (ADES) criteria, among patients diagnosed with dry eye disease under current hospital-based practice in Taiwan.

Detailed description

This real-world, observational study aims to show in a descriptive manner to characterize the patient profile of dry eye disease in Taiwan, and to understand the local practice and its difference compared with Asia Dry Eye Society (ADES) criteria. Specific objectives include:(1) to determine the proportion of patients diagnosed with dry eye by the Asia Dry Eye Society (ADES) criteria, among patients diagnosed with dry eye disease under current hospital-based practice in Taiwan, (2) to compare the patient profile including ocular condition and dry eye-related characteristics of dry eye diagnosed with ADES criteria versus hospital-based real-world practice in Taiwan, and (3) to determine the disease characteristics of patients diagnosed with dry eye in Taiwan medical institutions. This study will enroll patients who are diagnosed with dry eye, aged 20 years (inclusive), and are willing to provide signed informed consent. These patients will be categorized into Group I or II according to the inclusion criteria. Clinical data of eligible patients at the time of dry eye diagnosis on medical charts will be collected. If any return visit is scheduled per routine practice before the end of data collection (Feb-28-2022), follow-up data regarding dry eye evaluations and treatments will be collected at the first follow-up visit for Group I; and within 6 months after the cataract surgery for Group II.

Interventions

OTHERNo intervention

No intervention will be applied for the observational study.

Sponsors

Santen Pharmaceutical (Taiwan) Co., LTD
CollaboratorINDUSTRY
Kaohsiung Medical University
CollaboratorOTHER
Taipei Veterans General Hospital, Taiwan
CollaboratorOTHER_GOV
Far Eastern Memorial Hospital
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
CROSS_SECTIONAL

Eligibility

Sex/Gender
ALL
Age
20 Years to No maximum
Healthy volunteers
No

Inclusion criteria

Patients who meet the criteria of either Group I OR Group II are eligible. Group I Patients with signed informed consent and who satisfy all of the following criteria will be included: 1. 20 years old or older (regardless of sex) 2. Outpatients 3. Newly-diagnosed with dry eye disease (DED) within 6 months prior to signing the informed consent under hospital-based practice in Taiwan Group II Patients with signed informed consent and who satisfy all of the following criteria will be included: 1. 20 years old or older (regardless of sex) 2. Outpatients 3. Patients who had undergone cataract surgery and 1. was suspected to have dry eye disease (dry eye evaluations conducted based on the routine practice) within 6 months prior to signing the informed consent or 2. was diagnosed with dry eye disease within 6 months prior to signing the informed consent

Exclusion criteria

Patients who meet ANY one of the following criteria are not eligible. 1. Patients who have ocular comorbidities, and appear dry eye sign and symptoms that interfere with diagnosis of dry eye disease (DED) 2. Patients who cannot confirm subjective symptoms of dry eye 3. Patients who cannot read or write, and/or could not understand dry eye questionnaire appropriately which may compromise the accuracy of questionnaire score. 4. Patients who participate in other interventional trials in the past 30 days

Design outcomes

Primary

MeasureTime frameDescription
Proportion of patients who satisfy the criteria for dry eye disease based on the ADES criteriaAt the time of dry eye diagnosis (baseline)The criteria are defined by Asia Dry Eye Society (ADES).

Secondary

MeasureTime frameDescription
Proportion of patients per dry eye classificationFrom baseline to 6-month follow-upDry eye classification is judged by the investigator.
Length (mm) of soaked strip by tear for the dry eye diagnosisFrom baseline to 6-month follow-upUnanesthetized Schirmer's test is used for assessing the tear production.
Time (second) for tear film broken with fluorescein for the dry eye diagnosisFrom baseline to 6-month follow-upTear break-up time (TBUT) is used to assess for tear film (evaporative dry eye disease).
Score of Ocular Surface Disease Index (OSDI) for the dry eye symptomsFrom baseline to 6-month follow-upOcular Surface Disease Index (OSDI) questionnaire (0 to 100 points) is used to assess the dry eye symptoms. One hundred points mean that the dry eye disease of the patient is severe.
Score of Standard Patient Evaluation of Eye Dryness (SPEED) for the dry eye symptomsFrom baseline to 6-month follow-upStandard Patient Evaluation of Eye Dryness (SPEED) questionnaire (0 to 28 points) is used to assess the dry eye symptoms. Twenty-eight points mean that the symptoms of dry eye disease is severe.
Visual analogue scale (VAS) for the dry eye severityFrom baseline to 6-month follow-upVisual analogue scale (VAS) (0 to 10 \[mild to severe\]) is used to assess the dry eye severity based on the symptoms.
Difference in length (mm) of soaked strip by tear between patients who satisfy the criteria for dry eye disease based on the ADES consensus report and the whole population (i.e., hospital-based real-world practice)At the time of dry eye diagnosis (baseline)Unanesthetized Schirmer's test is used for assessing the tear production.
Difference in time (second) for tear film broken with fluorescein between patients who satisfy the criteria for dry eye disease based on the ADES consensus report and the whole population (i.e., hospital-based real-world practice)At the time of dry eye diagnosis (baseline)Tear break-up time (TBUT) is used to assess for tear film (evaporative dry eye disease).
Difference in score of Ocular Surface Disease Index (OSDI) between patients who satisfy the criteria for dry eye disease based on the ADES consensus report and the whole population (i.e., hospital-based real-world practice)At the time of dry eye diagnosis (baseline)Ocular Surface Disease Index (OSDI) questionnaire (0 to 100 points) is used to assess the dry eye symptoms. One hundred points mean that the dry eye disease of the patient is severe.
Proportion of patients per dry eye severityFrom baseline to 6-month follow-upDry eye severity (mild, moderate, severe) is judged by the investigator.
Difference in visual analogue scale (VAS) between patients who satisfy the criteria for dry eye disease based on the ADES consensus report and the whole population (i.e., hospital-based real-world practice)At the time of dry eye diagnosis (baseline)Visual analogue scale (VAS) (0 to 10 \[mild to severe\]) is used to assess the dry eye severity based on symptoms.
Proportion of patients who do not satisfy the criteria for dry eye disease based on the ADES per dry eye severityFrom baseline to 6-month follow-upDry eye severity (mild, moderate, severe) is judged by the investigator.
Proportion of patients who do not satisfy the criteria for dry eye disease based on the ADES per dry eye classificationFrom baseline to 6-month follow-upDry eye classification is judged by the investigator.
Length (mm) of soaked strip by tear using unanesthetized Schirmer test of patients who do not satisfy the criteria for dry eye disease based on the ADESFrom baseline to 6-month follow-upSchirmer's test is used for assessing the tear production.
Time (second) for tear film broken with fluorescein of patients who do not satisfy the criteria for dry eye disease based on the ADESFrom baseline to 6-month follow-upTear break-up time (TBUT) is used to assess for tear film (evaporative dry eye disease).
Score of Ocular Surface Disease Index (OSDI) of patients who do not satisfy the criteria for dry eye disease based on the ADESFrom baseline to 6-month follow-upOcular Surface Disease Index (OSDI) questionnaire (0 to 100 points) is used to assess the dry eye symptoms. One hundred points mean that the dry eye disease of the patient is severe.
Score of Standard Patient Evaluation of Eye Dryness (SPEED) of patients who do not satisfy the criteria for dry eye disease based on the ADESFrom baseline to 6-month follow-upStandard Patient Evaluation of Eye Dryness (SPEED) questionnaire (0 to 28 points) is used to assess the dry eye symptoms. Twenty-eight points mean that the symptoms of dry eye disease is severe.
Visual analogue scale (VAS) of patients who do not satisfy the criteria for dry eye disease based on the ADESFrom baseline to 6-month follow-upVisual analogue scale (VAS) (0 to 10 \[mild to severe\]) is used to assess the dry eye severity based on the symptoms.
Difference in score of Standard Patient Evaluation of Eye Dryness (SPEED) between patients who satisfy the criteria for dry eye disease based on the ADES consensus report and the whole population (i.e., hospital-based real-world practice)At the time of dry eye diagnosis (baseline)Standard Patient Evaluation of Eye Dryness (SPEED) questionnaire (0 to 28 points) is used to assess the dry eye symptoms. Twenty-eight points mean that the symptoms of dry eye disease is severe.

Countries

Taiwan

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026